Introduction
The practise of evidence-based medicine emphasizes the importance of the results of randomized controlled trials (RCTs) in guiding and justifying treatment decisions. 1 It is therefore crucial that such results are robust and that guideline writers and practitioners have a clinically meaningful and readily understandable method of evaluating robustness. Many clinicians, however, focus on relative risk reductions derived from hazard ratios, the 95% confidence intervals around these, and the threshold P-value of <0.05 which is commonly taken to denote statistical significance. 2 However, reliance on these metrics alone is of concern.
3 Implicit in the reporting of a relative risk reduction as 'significant' is the assumption that a true treatment effect exists. Sample size, number of events, and number of patients lost to follow-up, along with other factors including whether there is more than one trial, are also important determinants of the robustness of the findings. 4, 5 In order to assist the interpretation of trials an additional statistical metric, the 'fragility index' (FI), has been proposed as a tool to evaluate the robustness of results. 6 FI is the minimum number of events that need to change from a non-event to an event in order to render a significant result non-significant. The smaller the index, the more fragile the result. The principle underlying FI can be illustrated using an example of a trial with 100 patients randomized equally to treatment or placebo. If 10 patients in the treatment group experience an event, compared with 20 patients in the placebo group, the resultant P-value is 0.049 using a two-sided Fisher's exact test. If only one more event is added to the treatment group (n ¼ 11) while maintaining the same event rate in the placebo group, the trial loses 'significance' as the P-value increases to 0.083.
To explore the value of FI, we examined its use in assessing the robustness of the results of trials in chronic heart failure (HF) with reduced rejection fraction (HF-REF) as this is one of the most evidence-based areas in the whole of medicine. 7, 8 Multiple RCTs involving tens of thousands of patients have evaluated the effects of pharmacological and non-pharmacological therapies over the past 30 years. We analysed the trials providing the basis of guideline-recommended therapy in this condition. We also tested the value of three extensions of the FI concept. Firstly, we examined the FI for the different regulatory P-value thresholds for approval of a treatment based upon two independent trials compared with one single trial. Secondly, we studied the impact of loss to follow-up for vital status on the fragility of results. Finally, we explored the concept of FI applied to the results of a group of neutral trials in HF-REF.
Methods
We reviewed published guidelines for chronic HF-REF.
We identified trials used to support recommendations for pharmacological or nonpharmacological treatments. We calculated the FI for the reported outcomes in these trials. We also explored the relationships between trial characteristics and the fragility of the primary outcome.
Identification of studies
We searched the electronic databases Medline and Embase using the terms 'heart failure', 'management', and 'guidelines' as title or keywords published in English after January 2010. Guidelines and their most recent updates from five international bodies were identified. [7] [8] [9] [10] [11] These were examined to identify RCTs used to support the treatments in management algorithms for patients with HF-REF.
Positive RCTs published since guideline publication were included by consensus of the authors. Two reviewers (K.F.D. and R.T.C.) independently reviewed all identified abstracts. Trials were included if they reported at least one statistically significant dichotomous primary or secondary outcome (P < 0.05 or a 95% confidence interval that excluded the null value) and randomized patients to treatment or control in a 1:1 design. The FI is not suitable for use in situations where the ratio of intervention to control subjects is not 1:1 as altering the number of events in the control or intervention arm will lead to different results for the FI. 6, 12, 13 
Data analysed
Two reviewers independently screened the abstracts and full publications of included trials. They used a standard table to extract data from the trial and a third reviewer resolved any discrepancy. Data recorded included details of the primary outcome (sample size, event numbers, whether outcome was composite, and number lost to follow-up). We also recorded, where available, the details for the following additional outcomes: all-cause mortality, cardiovascular mortality, and HF hospitalization. If data were not available in the primary or subsequent trial publications, this information was then sought through correspondence with trial authors or from publically available Food and Drug Association (FDA) documentation.
FI calculation
Using the method described by Walsh et al. 6 FI for the statistically significant primary and secondary outcomes was calculated. We recorded the results for each outcome in a two-by-two contingency table. We calculated the P-value for each outcome using the twosided Fisher's exact test. One event at a time was iteratively added to the group with smaller number of events (while subtracting one patient from the group with no events to maintain the total number of patients constant) and the P-value for the two-by-two table calculated. The FI for an outcome was the smallest number of added events required to result in a P-value of 0.05 or greater (Supplementary mate rial online, Figure S1 ).
Statistical analysis
We report normally distributed and skewed continuous variables as means with standard deviations and medians with interquartile ranges (IQRs), respectively. We tested between group differences for significance using a Mann-Whitney U test for nonparametric data. Twosided significance testing was used and a P value <0.05 was considered significant. All analyses were performed using Microsoft Excel (Microsoft, Santa Rosa, CA, USA; 2015) and SPSS version 22 (IBM, Chicago, IL, USA; 2013). Correlations between FI and treatment effect-size, sample-size and number of events were calculated using the Spearman rank test for non-normal data. We also calculated the FI for two P-value thresholds: P < 0.05 (which is sufficient for regulatory approval when obtained in each of two independent trials) and for P < 0.00125 (the P-value required for regulatory approval if only one trial is submitted). Additionally, because loss to follow-up for vital status can reduce the integrity of a trial, we compared FI with the number lost to follow-up. The number of patients lost to follow-up included, where published, the number reported as having 'withdrawn consent' because, in many jurisdictions, this means that followup for vital status is not permitted. Finally, we extended the concept of FI to neutral trials (those with P 0.05) of treatments not advocated in the treatment of HF-REF. FI was calculated by subtracting events from the investigational treatment group (adding non-events to this group to keep number of patients constant) and calculating the Fisher's exact P-value. The FI was the number of events required to result in P < 0.05 (in other words, the outcome resulting in the investigational treatment demonstrating a statistically significant benefit).
Results

Trial selection
Five international guidelines on the management of chronic HF were identified and the most recent updates reviewed. Table S1 ).
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We excluded four trials because they did not allocate patients to treatment or comparator in a 1:1 ratio. Data were available for the three additional outcomes of interest (all-cause mortality, cardiovascular mortality, and HF hospitalization) in 21 (84%) trials. Information for one or two of these additional endpoints was missing in 3 (12%) and 1 (4%) trials respectively.
Trial characteristics
The effect of the investigational treatment on the primary endpoint was significant in 23 (92%) trials. Two trials (A-HeFT and IN-TIME) had significant composite score primary endpoints (non-dichotomous), meaning no FI was calculable (the dichotomous secondary endpoints were included in the analysis). 34, 45 Another trial (CHAMPION) used the primary endpoint of total number of HF hospitalizations which was not suitable for calculation of the FI (it did however have a secondary endpoint of number of patients hospitalized with HF which was included). 16 Therefore, we calculated FI for the primary outcome in 20 trials. The median number of patients with a primary outcome was 688.5 (range: 88-2031). The primary outcome was a composite in 11 (55%) of these trials. Reported P-values for the primary outcome were <0.05 but 0.01 in 4 (20%) trials, <0.01 but 0.001 in 7 (35%) trials, and <0.001 in 9 (45%) trials. The effect of treatment on the additional endpoints of all-cause mortality, cardiovascular mortality and HF hospitalization was significant in 16, 16 and 18 trials, respectively (not necessarily the same trials), and the median numbers of patients with these outcomes were 384 (range: 37-1546), 321.5 (29-1251) and 504.5 (134-2090), respectively.
Fragility index
Tables 2 and 3 summarize FI for the examined endpoints and according to different trial characteristics. The median FI for the primary endpoint in the 20 trials analysed was 26 (IQR: 8.5-39.25, range: 0-118) ( Table 3) . One trial had an FI of 0 ( Table 3) . 46 This trial was originally significant only after adjustment for predictors of the primary endpoint. The FI for trials with a composite outcome and those with a single primary endpoint was similar. The median FI for all-cause mortality, cardiovascular mortality and HF hospitalization was 13. Heart failure hospitalization (n=21) Reported P-value <0.05 18 (86) Number of outcome events, median (min-max) 504. 5 (134-2090) Values are given as n (%) unless otherwise stated. min, minimum; max, maximum; n, number. a The primary endpoint was significant in 23 of the 25 trials but 3 additional trials were excluded from fragility index analysis due to a non-dichotomous endpoint (A-HeFT and IN-TIME 34, 45 ) and an endpoint of total heart failure hospitalizations (CHAMPION 16 ). Primary endpoint was all-cause mortality at 6 months follow-up and number given for all-cause mortality relates to number of deaths at the completion of the trial. *P < 0.05 after adjustment, -not reported.
Correlation between Fragility index and sample-size, number of events, treatment effect-size, and P-value
Fragility index was not significantly correlated with total sample size (R ¼ 0.312, P ¼ 0.18) or number of patients experiencing the primary endpoint (R ¼ 0.007, P ¼ 0.977) ( Figure 1A and B) . There was no correlation between FI and the treatment/comparator hazard ratio (expressed as a relative risk reduction) for the primary endpoint or any of the other endpoints examined (Figure 2A-D) .
Fragility index for P-value thresholds of <0.05 and <0.00125
We calculated FI for P < 0.05 (sufficient for regulatory approval when obtained in each of two separate trials) and for P < 0.00125 (the P-value required for regulatory approval when a single trial is submitted). Of the 20 trials analysed, only 10 (50%) had an FI of >0 when considering the lower P-value (single trial) threshold ( Table 4 ). The median FI for these 10 trials was 18 (IQR: 7.5-30, range: 2-68).
Fragility index compared with number lost to follow-up for vital status
The number of patients lost to follow-up was available for all trials and was 1% of total sample size in 7 (35%) of the 20 trials examined in which the FI was calculated for the primary endpoint. The total number lost to follow-up in the treatment group was the same as or greater than the FI for the primary endpoint in 4 (20%) trials. These trials, their respective number lost to follow-up in the treatment group and FI for the primary endpoint were HEAAL (41 and 4), SENIORS (16 and 2), SHIFT (75 and 67), and HF-ACTION (59 and 0). 15, 24, 37, 46 Fragility index for neutral trials (P 0.05)
In the Supplementary material online, 
Discussion
We examined the robustness of the results of the trials supporting treatment recommendations in international HF-REF guidelines. The median FI for the primary endpoint in these trials was 26 (i.e. on average, 26 additional events were required to change a result from significant to non-significant). This compares favourably with the median of 8 found by Walsh et al. 6 in their original analysis of nearly 400 trials covering a spectrum of medical and surgical interventions. Indeed, in that previous study, 25% of trials had an FI of 3.
The lack of correlation between the treatment effect-size for the primary endpoint and FI illustrates how the result most practitioners focus on is an unreliable guide to the robustness of trial findings. Similarly, there was a lack of correlation between FI and either number of patients randomized or the number of patients experiencing a primary endpoint.
The recently published statement by the American Statistical Association regarding P-values has highlighted the issues surrounding the common reliance on the use of boundary P-values (most commonly <0.05) to infer statistical significance and the potential size of a treatment effect. 3 An important principle to stress is that a P-value, or statistical significance, does not measure the size of an effect or the importance of a result. Most clinical trials are designed on the basis of event-rates and sample sizes large enough to accrue an adequate number of events to provide sufficient power to allow robust assessment of the treatment effect. Despite this, as we have shown, the FI varies widely among trials. This variation reflects a number of factors including the anticipated treatment effect-size, event rates, and the power of the study (e.g. 80% or 90%). Although early stopping for efficacy might in theory lead to a small FI, we found FI was actually higher in those trials, presumably reflecting the stringent stopping rules employed and the rarity of very early termination.
Based on the strength, depth, and breadth of evidence available, international guidelines for HF-REF give the strongest recommendation (i.e. Class 1, level A) to five treatments: angiotensin-converting enzyme inhibitors (ACE-Is), beta-blockers, mineralocorticoid receptor antagonists (MRAs), implantable cardioverter-defibrillators (ICD), and cardiac resynchronization therapy (CRT). [7] [8] [9] [10] [11] The three cornerstones of pharmacological therapy, ACE-Is, beta-blockers, and MRAs, had median FI of 8.5, 33 and 57.5, respectively, based on the primary endpoints in the relevant trials. However, the primary endpoint contributing to each of these estimates differed among trials, making direct comparison difficult. This is best illustrated by the two pivotal MRA trials, RALES and EMPHASIS-HF, in which the FI for the primary endpoint was 54 and 61, respectively. 32, 33 However, for all-cause mortality the FI was 54 and 5, respectively (all-cause mortality was the primary endpoint in RALES whereas the composite of cardiovascular death or HF hospitalization was in EMPHASIS-HF). This illustrates the importance of 'like-with-like' comparisons when examining endpoints across trials, which we believe is the most appropriate way to compare outcomes. The difference observed probably reflects the smaller number of deaths in EMPHASIS-HF compared with RALES due to the different patients enrolled, the different eras in which these two trials were conducted (RALES preceded use of beta-blockers and devices), and the premature termination of EMPHASIS-HF. Both trials, however, showed a robust treatment effect on HF hospitalization (FI 41 and 49, respectively). Of course, it is also important that there are two large trials with an MRA in chronic HF-REF and a supporting trial in patients with left ventricular systolic dysfunction (LVSD) and HF (or diabetes mellitus) after myocardial infarction (MI). 71 The relatively lower FI for ACE-Is is of interest given that these are the longest-standing evidence-based treatment in HF-REF. The two trials supporting the use of ACE-I, CONSENSUS and SOLVD-T, had an FI for the primary endpoint (all-cause mortality) of 7 and 10, respectively.
14, 17 The low FI in CONSENSUS is due to few deaths, related to the small sample size (n ¼ 253) and premature trial termination. However, SOLVD-T was 10 times as large and accrued eight times as many deaths but still had a modest FI for all-cause mortality. The effect of enalapril on HF hospitalization in SOLVD-T was, by comparison, very robust, with an FI of 91. Also, as with MRAs, any concern about robustness is further alleviated by having supporting trials in patients LVSD, HF or both after MI, as well as a trial in patients with chronic asymptomatic LVSD. [72] [73] [74] [75] Of the current key pharmacological interventions, beta-blockers had the most consistent and robust effect on all-cause mortality with three placebo-controlled trials and one active-controlled trial with FI of over 30 for all-cause mortality and similarly large FI for HF hospitalization. One trial in much older patients, not all of which had HF-REF, did not show a reduction in mortality. Although this difference may reflect the patients enrolled, it is also possible that the beta-blocker studied was less effective. 76 The two CRT trials with 1:1 randomization, CARE-HF and RAFT, each had a robust FI for the primary endpoint (40 and 23, respectively), as well as for mortality and HF hospitalization and are supported by two other trials without 1:1 randomization. 41, 42, 48, 49 The largest FI (118) for any primary endpoint was obtained in PARADIGM-HF which compared the angiotensin neprilysin inhibitor sacubitril/valsartan with enalapril. 38 This trial also had one of the highest FI for all-cause mortality, at 49 (second only to RALES). PARADIGM-HF also highlights an extension to the basic FI metric that might be added in future analyses. Unlike the other drugs discussed above, there is only one trial supporting the use of sacubitril/ valsartan. An additional measure that could be included in this situation is calculation of the FI not only for P < 0.05 (sufficient for regulatory approval when obtained in each of two separate trials) but also for P < 0.00125 (the P-value required for regulatory approval if only one trial is available). Using this criterion, the FI for the primary endpoint fell to 68 in PARADIGM-HF. When the same approach was Clinical trials in HF applied to SHIFT, the FI also remained relatively robust (22) . 37 However, in REMATCH (a controlled trial of a first-generation left ventricular assist device) the FI fell to 3 and in SCD-HeFT (the only trial of an ICD in patients with chronic HF-REF), the FI fell to zero. 39, 43 In other single trials, neither digoxin nor exercise prescription improved the primary outcome. 36, 46 In the trial using the combination of hydralazine and isosorbide dinitrate, the primary outcome was not dichotomous and the FI for the secondary endpoints of allcause and cardiovascular mortality were fragile, with an FI of 3 and 2, respectively. 34 There is also uncertainty about the robustness of the benefit of remote monitoring interventions. 16, 45 Another extension of the basic FI calculation we recommend is comparison with the number of patients lost to follow-up for vital status. The total number of patients lost to follow-up for vital status in the treatment arm was greater than the FI in four trials. The implication of this is similar to the 'worst case scenario' sometimes used by regulatory agencies in which all patients lost in the placebo group are considered alive and those lost in the active therapy group considered dead. As a result, even if a trial has a large FI, the results may not be as robust as they might seem. Take for example SHIFT, which had an FI of 67 for the primary outcome, although no significant effect on cardiovascular or all-cause mortality. Assuming withdrawal-ofconsent equated to lost to follow-up for vital status, then 75 patients in the ivabradine group would have missing vital status, a number considerably larger than the FI.
The extension of the concept of FI to neutral trials is also of interest as, in the same way, a large FI provides assurance about the robustness of the results, i.e. that the neutral outcome is likely to be true rather than due to deficiencies in trial design or conduct, e.g. inadequate power, too few events, an anticipated treatment effect that was optimistically large, etc. Our analysis of 20 trials showed that the median FI was 30, suggesting that the majority of neutral trials examined can be considered to be robust. The one exception was STICH, a trial with an FI of 5 (the lowest of all the neutral trials) which investigated the effect of coronary-artery bypass grafting (CABG) in addition to medical therapy in patients with HF-REF and coronaryartery disease. 51 This means that five fewer deaths in the CABG arm of the trial would have resulted in a statistically significant result (measured by Fisher's exact test). This may be a particular issue in surgical trials where there is always a small initial excess of deaths in the active intervention arm, with later 'catch-up' if the surgery is beneficial. In keeping with this, the recently published 10-year extended follow-up of this trial demonstrated a significantly lower mortality in the CABG group compared with the medical therapy group. 77 This illustrates the potential value of extended follow-up in surgical (and potentially other) trials provided the number of patients lost to follow-up of vital status is kept low. Our analysis has limitations. The concept of the FI can only be applied to dichotomous endpoints although the majority of RCTs supporting guidelines is likely to be based on dichotomous endpoints. Walsh et al. 6 found no material difference in the FI between time-toevent data and frequency data, which they considered consistent with the concept that most results are sensitive to the number of events in each group rather than the timing of the events. Nevertheless, there may still be a concern about applying the FI to time-to-event data where the numbers of events in both groups are similar but there is a clear difference in the timing of the events. This could result in the inappropriate conclusion that such trials are excessively fragile. We have also mitigated this concern for composite time-to-event endpoints by calculating the FI for the individual components (all-cause mortality, cardiovascular mortality, and HF hospitalization) of these endpoints. We examined a moderate number of trials; therefore, our ability to draw inference regarding the relationship between trial characteristics and FI is limited. Certain treatments were not as well represented as others, in particular devices, due to the majority of trials not using 1:1 randomization. Because trials are powered to detect the presence of a treatment effect for the primary endpoint, interpretation of the fragility of secondary endpoints may be limited.
Conclusion
The FI offers an additional and easy to understand metric to the standard reporting of hazard ratios, 95% confidence intervals, and 
